Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 692

1.

Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.

Shojaei F, Ferrara N.

Drug Resist Updat. 2008 Dec;11(6):219-30. doi: 10.1016/j.drup.2008.09.001. Epub 2008 Oct 23. Review.

PMID:
18948057
[PubMed - indexed for MEDLINE]
2.

Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies.

Crawford Y, Ferrara N.

Trends Pharmacol Sci. 2009 Dec;30(12):624-30. doi: 10.1016/j.tips.2009.09.004. Review.

PMID:
19836845
[PubMed - indexed for MEDLINE]
3.

Pathways mediating VEGF-independent tumor angiogenesis.

Ferrara N.

Cytokine Growth Factor Rev. 2010 Feb;21(1):21-6. doi: 10.1016/j.cytogfr.2009.11.003. Epub 2009 Dec 11. Review.

PMID:
20005148
[PubMed - indexed for MEDLINE]
4.

Targeting the tumor stroma in cancer therapy.

Anton K, Glod J.

Curr Pharm Biotechnol. 2009 Feb;10(2):185-91. Review.

PMID:
19199950
[PubMed - indexed for MEDLINE]
5.

Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.

Miletic H, Niclou SP, Johansson M, Bjerkvig R.

Expert Opin Ther Targets. 2009 Apr;13(4):455-68. doi: 10.1517/14728220902806444 . Review.

PMID:
19335067
[PubMed - indexed for MEDLINE]
6.

III. Angiogenesis: complexity of tumor vasculature and microenvironment.

Furuya M, Yonemitsu Y, Aoki I.

Curr Pharm Des. 2009;15(16):1854-67. Review.

PMID:
19519428
[PubMed - indexed for MEDLINE]
7.

VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy.

Greenberg JI, Cheresh DA.

Expert Opin Biol Ther. 2009 Nov;9(11):1347-56. doi: 10.1517/14712590903208883. Review.

PMID:
19761418
[PubMed - indexed for MEDLINE]
8.

Vascular endothelial growth factor as a therapeutic target in cancer.

Bergsland EK.

Am J Health Syst Pharm. 2004 Nov 1;61(21 Suppl 5):S4-11. Review.

PMID:
15552621
[PubMed - indexed for MEDLINE]
9.

Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis.

Ferrara N.

Curr Opin Hematol. 2010 May;17(3):219-24. doi: 10.1097/MOH.0b013e3283386660. Review.

PMID:
20308892
[PubMed - indexed for MEDLINE]
10.

Vascular endothelial growth factor and its inhibitors.

Verheul HM, Pinedo HM.

Drugs Today (Barc). 2003;39 Suppl C:81-93. Review.

PMID:
14988747
[PubMed - indexed for MEDLINE]
11.

Angiogenesis inhibitors. Drug selectivity and target specificity.

Kesisis G, Broxterman H, Giaccone G.

Curr Pharm Des. 2007;13(27):2795-809. Review.

PMID:
17897024
[PubMed - indexed for MEDLINE]
12.

Molecular and cellular regulators of cancer angiogenesis.

Goh PP, Sze DM, Roufogalis BD.

Curr Cancer Drug Targets. 2007 Dec;7(8):743-58. Review.

PMID:
18220534
[PubMed - indexed for MEDLINE]
13.

Tumor angiogenesis and therapy.

Cao Y.

Biomed Pharmacother. 2005 Oct;59 Suppl 2:S340-3. Review.

PMID:
16507405
[PubMed - indexed for MEDLINE]
14.

Angiogenesis: a target for cancer therapy.

Tortora G, Melisi D, Ciardiello F.

Curr Pharm Des. 2004;10(1):11-26. Review.

PMID:
14754402
[PubMed - indexed for MEDLINE]
15.

The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials.

Rüegg C, Meuwly JY, Driscoll R, Werffeli P, Zaman K, Stupp R.

Curr Mol Med. 2003 Dec;3(8):673-91. Review.

PMID:
14682490
[PubMed - indexed for MEDLINE]
16.

Anti-angiogenic therapies in cancer: achievements and open questions.

Ruegg C, Mutter N.

Bull Cancer. 2007 Sep;94(9):753-62. Review.

PMID:
17878094
[PubMed - indexed for MEDLINE]
17.

Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications.

Harper J, Moses MA.

EXS. 2006;(96):223-68. Review.

PMID:
16383021
[PubMed - indexed for MEDLINE]
18.

Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.

De Bock K, Cauwenberghs S, Carmeliet P.

Curr Opin Genet Dev. 2011 Feb;21(1):73-9. doi: 10.1016/j.gde.2010.10.008. Epub 2010 Nov 22. Review.

PMID:
21106363
[PubMed - indexed for MEDLINE]
19.

Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.

Glade Bender J, Cooney EM, Kandel JJ, Yamashiro DJ.

Drug Resist Updat. 2004 Aug-Oct;7(4-5):289-300. Review.

PMID:
15533766
[PubMed - indexed for MEDLINE]
20.

Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.

Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, Presta M.

Eur Cytokine Netw. 2009 Dec;20(4):225-34. doi: 10.1684/ecn.2009.0175. Review.

PMID:
20167562
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk